Prescription Drug Price Relief Act of 2019

Summary

Prescription Drug Price Relief Act of 2019 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 10 January 2019

   Referred

   Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

   Source: Committee

2. 10 January 2019

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 10 January 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 10 January 2019

   Introduced

   Introduced in House

   Source: IntroReferral

5. 25 January 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 10 January 2019 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 10 January 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 10 January 2019

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 10 January 2019

  Open at official source

Sponsors

• Rep. Khanna, Ro [D-CA-17] · D · Sponsor
• Sen. Welch, Peter [D-VT] · D · Sponsor
• ELIJAH CUMMINGS · D · Sponsor
• Alexandria Ocasio-Cortez · D · Sponsor
• Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Rep. Omar, Ilhan [D-MN-5] · D · Sponsor
• Rosa DeLauro · D · Sponsor
• Rep. Neguse, Joe [D-CO-2] · D · Sponsor
• Barbara Lee · D · Sponsor
• Rep. Tlaib, Rashida [D-MI-12] · D · Sponsor
• Rep. Pressley, Ayanna [D-MA-7] · D · Sponsor
• Tulsi Gabbard · D · Sponsor
• PETER DEFAZIO · D · Sponsor
• Rep. Jayapal, Pramila [D-WA-7] · D · Sponsor
• Rep. DeSaulnier, Mark [D-CA-10] · D · Cosponsor
• Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
• Debra Haaland · D · Cosponsor
• Debbie Mucarsel-Powell · D · Cosponsor
• Rep. Davis, Danny K. [D-IL-7] · D · Cosponsor
• Rep. Raskin, Jamie [D-MD-8] · D · Cosponsor
• LUCILLE ROYBAL-ALLARD · D · Cosponsor
• Rep. Meng, Grace [D-NY-6] · D · Cosponsor
• · hsif00 · Standing
• · hsju00 · Standing

Related records

• related to → Prescription Drug Price Relief Act of 2021
• related to → Prescription Drug Price Relief Act of 2019